[cv]

Improving Pretargeted Radioimmunotherapy

Currently, antibodies conjugated to radiometals are used clinically for the treatment of Non-Hodgkin's lymphoma; however radioimmunotherapy is limited by non-specific radiation of normal tissues due to long antibody half-lives in the blood. Pretargeted radioimmunotherapy decouples the pharmacokinetics of the antibody and radiometal, increasing efficacy and decreasing toxicity. However, there are still challenges to efficacious treatment including effective radionuclide capture, immune reactions, and cellular trafficking resulting in incomplete penetration of antibody into large tumor masses. My research will focus on developing optimized delivery strategies to maximize therapeutic dosing to cancer cells while minimizing toxicity and immune responses.